The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).
David Shao Peng Tan
No relevant relationships to disclose
Christian K. Kollmannsberger
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Sebastien J. Hotte
No relevant relationships to disclose
David W. Cescon
No relevant relationships to disclose
Ivan Diaz-Padilla
No relevant relationships to disclose
David W. Hedley
No relevant relationships to disclose
Daniel John Renouf
Honoraria - Amgen
Albiruni R.A. Razak
No relevant relationships to disclose
Karen A. Gelmon
Consultant or Advisory Role - Amgen; Pfizer
Hal W. Hirte
No relevant relationships to disclose
Lisa Wang
No relevant relationships to disclose
Monika Wizemann
No relevant relationships to disclose
Jeffrey Moscow
No relevant relationships to disclose
Helen X. Chen
No relevant relationships to disclose
Lillian L. Siu
Employment or Leadership Position - Agios (I); EntreMed (I)
Consultant or Advisory Role - Boehringer Ingelheim; Oncoethix
Stock Ownership - Agios (I); EntreMed (I); Rigel Pharmaceuticals Inc. (I)
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck; Novartis; Pfizer; Regeneron
Philippe L. Bedard
No relevant relationships to disclose